ServiceNow Inc vs Pfizer Inc — how do they compare? ServiceNow Inc trades at $141.04 (market cap $144.48B), while Pfizer Inc trades at $27.9 (market cap $158.56B). The key difference: ServiceNow Inc and Pfizer Inc are close in size by market cap, and Pfizer Inc pays a 6.18% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ServiceNow Inc for 54 Days and Pfizer Inc for 158 Days on average.
| NOW | PFE | |
|---|---|---|
Market Cap | $144.48B | $158.56B |
Volume | 11,801,699 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $189.26 | $29.02 |
52-Week Low | $83.00 | $23.67 |
Typical Hold Time | 54 Days | 158 Days |
Enterprise Value | $148.27B | $210.06B |
Dividend Yield | — | 6.18% |
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $137.87, down slightly by 0.07% on the day. The stock shows strong fundamental momentum with revenue growing from $7.2B in 2022 to $13.3B in 2025 and consistent earnings beats in recent quarters. Technical indicators are bullish with the price above key moving averages, while analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $146.04 consensus target. The company's AI business has surpassed $1 billion in annual contract value, driving investor optimism.
ServiceNow presents a compelling growth story with robust AI adoption and expanding enterprise workflow solutions. The primary investment opportunity lies in the company's leadership position in enterprise AI and strong subscription revenue growth. Key risks include premium valuation multiples (P/E of 87.34), increasing competition in cloud software, and potential margin pressure as AI investments scale. The stock offers upside to analyst targets but requires monitoring of execution against ambitious growth projections.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →